Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, Madrid, Spain; 2 Health Research Institute (IiGSM), School of Medicine, Universidad Complutense de Madrid, Madrid, Spain; 3 Biomedical Research Center for Mental Health (CIBERSAM), Madrid, Spain; 4 Pain and Rehabilitation Centre and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden; 5 Early Psychosis: Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK; 6 Department of Neuroscience, University of Padua, Padua, Italy; 7 Department of Psychiatry, University of Ottawa and Department of Mental Health, Ottawa Hospital, Ottawa, ON, Canada; 8 Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK; 9 Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK; 10Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK; 11Hassenfeld Children’s Hospital at NYU Langone, New York, NY, USA; 12Department of Psychiatry and Psychotherapy, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany; 13Centerfor Basicsin NeuroModulation, Faculty of Medicine, University of Freiburg, Freiburg, Germany; 14Department of Psychosis Studies, King’s College London, London, UK; 15Department of Psychiatry, University of Cambridge, Cambridge, UK; 16CAMEO Early Intervention Service, Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge, UK; 17Department of Psychiatry, Dalhousie University, Halifax, NS, Canada; 18Nova Scotia Health, Halifax, NS, Canada; 19IWK Health Centre, Halifax, NS, Canada; 20Department of Medical Neuroscience, Dalhousie University, Halifax, NS, Canada; 21IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, Geelong, VIC, Australia; 22Department of Psychiatry, University of Toronto, and Centre for Addiction and Mental Health, Toronto, ON, Canada; 23Department of Psychiatry, Icahn School of Medicine at Mount Sinai, NewYork, NY, USA; 24Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 25Seaver Center for Autism Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 26Department of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea; 27Department of Pediatrics, Severance Children’s Hospital, Seoul, South Korea; 28NORMENT – Institute of Clinical Medicine, Division of Mental Health and Addiction, University of Oslo and Oslo University Hospital, Oslo, Norway; 29Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA; 30Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; 31Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA; 32Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; 33OASIS Service, South London and Maudsley NHS Foundation Trust, London, UK; 34Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
Список исп. литературыСкрыть список
1. Rasic D, Hajek T, Alda M et al. Risk of mental illness in offspring of parents with schizophrenia, bipolar disorder, and major depressive disorder: a metaanalysis of family high-risk studies. Schizophr Bull 2014;40:28-38.
2. Lo LE, Kaur R, Meiser B et al. Risk of schizophrenia in relatives of individuals affected by schizophrenia: a meta-analysis. Psychiatry Res 2020;286: 112852.
3. Pepper EJ, Pathmanathan S, McIlrae S et al. Associations between risk factors for schizophrenia and concordance in four monozygotic twin samples. Am J Med Genet B Neuropsychiatr Genet 2018;177:503-10.
4. Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience 2009; 164:331-43.
5. Chen MH, Hsu JW, Huang KL et al. Risk and coaggregation of major psychiatric disorders among first-degree relatives of patients with bipolar disorder: a nationwide population-based study. Psychol Med 2019;49:2397-404.
6. Tortella-Feliu M, Fullana MA, Perez-Vigil A et al. Risk factors for posttraumatic stress disorder: an umbrella review of systematic reviews and metaanalyses. Neurosci Biobehav Rev 2019;107:154-65.
7. McGuffin P, Katz R, Watkins S et al. A hospital-based twin register of the heritability of DSM-IV unipolar depression. Arch Gen Psychiatry 1996;53:129-36.
8. Wray NR, Lin T, Austin J et al. From basic science to clinical application of polygenic risk scores: a primer. JAMA Psychiatry 2021;78:101-09.
9. The Schizophrenia Working Group of the Psychiatric Genomics Consortium. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. medRxiv 2020;20192922.
10. Marsman A, Pries LK, Ten Have M et al. Do current measures of polygenic risk for mental disorders contribute to population variance in mental health? Schizophr Bull 2020;46:1353-362.
11. Uher R, Zwicker A. Etiology in psychiatry: embracing the reality of poly-geneenvironmental causation of mental illness. World Psychiatry 2017;16:121-9.
12. Moe RH, Haavardsholm EA, Christie A et al. Effectiveness of nonpharmacological and nonsurgical interventions for hip osteoarthritis: an umbrella review of high-quality systematic reviews. Phys Ther 2007;87:1716-27.
13. Fusar-Poli P, Radua J. Ten simple rules for conducting umbrella reviews. Evid Based Ment Health 2018;21:95-100.
14. Ioannidis JP. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments metaanalyses. CMAJ 2009;181:488-93.
15. Radua J, Ramella-Cravaro V, Ioannidis JPA et al. What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry 2018;17:49-66.
16. Aromataris E, Fernandez R, Godfrey CM et al. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc 2015;13:132-40.
17. Theodoratou E, Tzoulaki I, Zgaga L et al. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014;348:g2035.
18. Bellou V, Belbasis L, Tzoulaki I et al. Environmental risk factors and Parkinson’s disease: an umbrella review of meta-analyses. Parkinsonism Relat Disord 2016;23:1-9.
19. Belbasis L, Bellou V, Evangelou E et al. Environmental factors and risk of multiple sclerosis: findings from meta-analyses and Mendelian randomization studies. Mult Scler 2020;26:397-404.
20. Belbasis L, Bellou V, Evangelou E et al. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol 2015;14:263-73.
21. Dragioti E, Solmi M, Favaro A et al. Association of antidepressant use with adverse health outcomes: a systematic umbrella review. JAMA Psychiatry 2019;76:1241-55.
22. Fusar-Poli P, Hijazi Z, Stahl D et al. The science of prognosis in psychiatry: a review. JAMA Psychiatry 2018;75:1289-97.
23. Mentis AA, Dardiotis E, Efthymiou V et al. Non-genetic risk and protective factors and biomarkers for neurological disorders: a meta-umbrella systematic review of umbrella reviews. BMC Med 2021;19:6.
24. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9.
25. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336: 924-6.
26. Guyatt G, Oxman AD, Akl EA et al. GRADE guidelines: 1. Introduction -GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-94.
27. Bellou V, Belbasis L, Tzoulaki I et al. Systematic evaluation of the associations between environmental risk factors and dementia: an umbrella review of systematic reviews and meta-analyses. Alzheimers Dement 2017;13:406-18.
28. Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA 2016;316:1818-9.
29. Shea BJ, Reeves BC, Wells G et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008.
30. Fusar-Poli P. TRANSD recommendations: improving transdiagnostic research in psychiatry. World Psychiatry 2019;18:361-2.
31. Fusar-Poli P, Solmi M, Brondino N et al. Transdiagnostic psychiatry: a systematic review. World Psychiatry 2019;18:192-207.
32. Bortolato B, Kohler CA, Evangelou E et al. Systematic assessment of environmental risk factors for bipolar disorder: an umbrella review of systematic reviews and meta-analyses. Bipolar Disord 2017;19:84-96.
33. Belbasis L, Kohler CA, Stefanis N et al. Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses. Acta Psychiatr Scand 2018;137:88-97.
34. Kohler CA, Evangelou E, Stubbs B et al. Mapping risk factors for depression across the lifespan: an umbrella review of evidence from meta-analyses and Mendelian randomization studies. J Psychiatr Res 2018;103:189-207.
35. Kim JY, Son MJ, Son CY et al. Environmental risk factors and biomarkers for autism spectrum disorder: an umbrella review of the evidence. Lancet Psychiatry 2019;6:590-600.
36. Fullana MA, Tortella-Feliu M, Fernandez de la Cruz L et al. Risk and protective factors for anxiety and obsessive-compulsive disorders: an umbrella review of systematic reviews and meta-analyses. Psychol Med 2020;50:1300-15.
37. Kim JH, Kim JY, Lee J et al. Environmental risk factors, protective factors, and peripheral biomarkers for ADHD: an umbrella review. Lancet Psychiatry 2020;7:955-70.
38. Solmi M, Civardi S, Corti R et al. Risk and protective factors for alcohol and tobacco related disorders: an umbrella review of observational studies. Neurosci Biobehav Rev 2020;121:20-8.
39. Solmi M, Dragioti E, Arango C et al. Risk and protective factors for mental disorders with onset in childhood/adolescence: an umbrella review of published meta-analyses of observational longitudinal studies. Neurosci Biobehav Rev 2021;120:565-73.
40. Solmi M, Radua J, Stubbs B et al. Risk factors for eating disorders: an umbrella review of published meta-analyses. Braz J Psychiatry (in press).
41. Solmi M, Dragioti E, Croatto G et al. Risk and protective factors for cannabis, cocaine, and opioid use disorders: an umbrella review of meta-analyses of observational studies. Neurosci Biobehav Rev 2021;126:243-51.
42. Solmi M, Dragioti E, Croatto G et al. Risk and protective factors for personality disorders: an umbrella review of published meta-analyses of case-control and cohort studies. Submitted for publication.
43. Salazar de Pablo G, Studerus E, Vaquerizo-Serrano J et al. Implementing precision psychiatry: a systematic review of individualized prediction models for clinical practice. Schizophr Bull 2021;47:284-97.
44. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature 2010;468:203-12.
45. Hofler M. The Bradford Hill considerations on causality: a counterfactual perspective. Emerg Themes Epidemiol 2005;2:11.
46. Lucas RM, McMichael AJ. Association or causation: evaluating links between “environment and disease”. Bull World Health Organ 2005;83:792-5.
47. Halvorsen A, Hesel B, Ostergaard SD et al. In utero exposure to selective serotonin reuptake inhibitors and development of mental disorders: a systematic review and meta-analysis. Acta Psychiatr Scand 2019;139:493-507.
48. Maj M, van Os J, De Hert M et al. The clinical characterization of the patient with primary psychosis aimed at personalization of management. World Psychiatry 2021;20:4-33.
49. Maj M, Stein DJ, Parker G et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry 2020;19:269-3.
50. Reynolds CF 3rd. Optimizing personalized management of depression: the importance of real-world contexts and the need for a new convergence paradigm in mental health. World Psychiatry 2020;19:266-8.
51. Leavell H, Clark E. Preventive medicine for the doctor in his community: an epidemiologic approach, 1st ed. New York: McGraw-Hill, 1958.
52. Arango C, Diaz-Caneja CM, McGorry PD et al. Preventive strategies for mental health. Lancet Psychiatry 2018;5:591-604.
53. Yeh SW, Lin LF, Chen HC et al. High-intensity functional exercise in older adults with dementia: a systematic review and meta-analysis. Clin Rehabil 2021;35:169-81.
54. Vancampfort D, Firth J, Schuch FB et al. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry 2017;16:308-15.
55. Stubbs B, Vancampfort D, Hallgren M et al. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and position statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry 2018;54:124-44.
56. Ashdown-Franks G, Firth J, Carney R et al. Exercise as medicine for mental and substance use disorders: a meta-review of the benefits for neuropsychiatric and cognitive outcomes. Sports Med 2020;50:151-70.
57. Firth J, Siddiqi N, Koyanagi A et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 2019;6:675-712.
58. Firth J, Solmi M, Wootton RE et al. A meta-review of “lifestyle psychiatry”: the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry 2020;19:360-80.
59. Di Forti M, Marconi A, Carra E et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2015;2:233-8.
60. Brown TJ, Todd A, O’Malley C et al. Community pharmacy-delivered interventions for public health priorities: a systematic review of interventions for alcohol reduction, smoking cessation and weight management, including meta-analysis for smoking cessation. BMJ Open 2016;6:e009828.
61. Wray JM, Funderburk JS, Acker JD et al. A meta-analysis of brief tobacco interventions for use in integrated primary care. Nicotine Tob Res 2018;20:1418-26.
62. Pearsall R, Smith DJ, Geddes JR. Pharmacological and behavioural interventions to promote smoking cessation in adults with schizophrenia and bipolar disorders: a systematic review and meta-analysis of randomised trials. BMJ Open 2019;9:e027389.
63. Siskind DJ, Wu BT, Wong TT et al. Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders: a systematic review, meta-analysis, and network meta-analysis. Lancet Psychiatry 2020; 7:762-74.
64. Peckham E, Brabyn S, Cook L et al. Smoking cessation in severe mental ill health: what works? An updated systematic review and meta-analysis. BMC Psychiatry 2017;17:252.
65. Claire R, Chamberlain C, Davey MA et al. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2020;3:CD010078.
66. Coronado-Montoya S, Morissette F, Abdel-Baki A et al. Preventive interventions targeting cannabis use and related harms in people with psychosis: a systematic review. Early Interv Psychiatry (in press).
67. O’Connor E, Thomas R, Senger CA et al. Interventions to prevent illicit and nonmedical drug use in children, adolescents, and young adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2020;323:2067-79.
68. Baumeister D, Akhtar R, Ciufolini S et al. Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-alpha. Mol Psychiatry 2016;21:642-9.
69. US Preventive Services Task Force, Curry SJ, Krist AH et al. Interventions to prevent child maltreatment: US Preventive Services Task Force recommendation statement. JAMA 2018;320:2122-8.
70. Lund C, Brooke-Sumner C, Baingana F et al. Social determinants of mental disorders and the sustainable development goals: a systematic review of reviews. Lancet Psychiatry 2018;5:357-69.
71. Catalan A, Salazar de Pablo G, Vaquerizo Serrano J et al. Annual research review: Prevention of psychosis in adolescents – systematic review and meta-analysis of advances in detection, prognosis and intervention. J Child Psychol Psychiatry 2021;62:657-73.
72. Fusar-Poli P, Tantardini M, De Simone S et al. Deconstructing vulnerability for psychosis: meta-analysis of environmental risk factors for psychosis in subjects at ultra high-risk. Eur Psychiatry 2017;40:65-75.
73. Oliver D, Reilly T, Baccaredda Boy O et al. What causes the onset of psychosis in individuals at clinical high risk? A meta-analysis of risk and protective factors. Schizophr Bull 2020;46:110-20.
74. Fusar-Poli P, Schultze-Lutter F, Cappucciati M et al. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull 2016;42:732-43.
75. Salazar de Pablo G, Catalan A, Fusar-Poli P. Clinical validity of DSM-5 attenuated psychosis syndrome: advances in diagnosis, prognosis, and treatment. JAMA Psychiatry 2020;77:311-20.
76. Fusar-Poli P, De Micheli A, Chalambrides M, et al. Unmet needs for treatment in 102 individuals with brief and limited intermittent psychotic symptoms (BLIPS): implications for current clinical recommendations. Epidemiol Psychiatr Sci 2019;29:e67.
77. Fusar-Poli P, Cappucciati M, De Micheli A et al. Diagnostic and prognostic significance of brief limited intermittent psychotic symptoms (BLIPS) in individuals at ultra high risk. Schizophr Bull 2017;43:48-56.
78. Fusar-Poli P, Cappucciati M, Bonoldi I et al. Prognosis of brief psychotic episodes: a meta-analysis. JAMA Psychiatry 2016;73:211-20.
79. Fusar-Poli P, Salazar De Pablo G, Rajkumar R et al. Diagnosis, prognosis and treatment of brief psychotic episodes: a review and research agenda. Lancet Psychiatry (in press).
80. Chen H, Cohen P, Chen S. How big is a big odds ratio? interpreting the magnitudes of odds ratios in epidemiological studies. Commun Stat-Simul C 2010;39:860-4.
81. Henriksen MG, Nordgaard J, Jansson LB. Genetics of schizophrenia: overview of methods, findings and limitations. Front Hum Neurosci 2017;11:322.
82. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013;381:1371-9.
83. Caspi A, Houts RM, Belsky DW et al. The p factor: one general psychopathology factor in the structure of psychiatric disorders? Clin Psychol Sci 2014;2:119-37.
84. Carvalho AF, Solmi M, Sanches M et al. Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. Transl Psychiatry 2020;10:152.
85. Hartman CA. The important gain is that we are lumpers and splitters now; it is the splitting that needs our hard work. World Psychiatry 2021;20:72-3.
86. Sanislow CA. RDoC at 10: changing the discourse for psychopathology. World Psychiatry 2020;19:311-2.
87. Oliver D, Spada G, Englund A et al. Real-world digital implementation of the Psychosis Polyrisk Score (PPS): a pilot feasibility study. Schizophr Res 2020;226:176-83.
88. Hickie IB. The role of new technologies in monitoring the evolution of psychopathology and providing measurement-based care in young people. World Psychiatry 2020;19:38-9.
89. Schmidt A, Cappucciati M, Radua J et al. Improving prognostic accuracy in subjects at clinical high risk for psychosis: systematic review of predictive models and meta-analytical sequential testing simulation. Schizophr Bull 2017;43:375-88.
90. Oliver D, Radua J, Reichenberg A et al. Psychosis Polyrisk Score (PPS) for the detection of individuals at-risk and the prediction of their outcomes. Front Psychiatry 2019;10:174.
91. Pries LK, Erzin G, van Os J et al. Predictive performance of exposome score for schizophrenia in the general population. Schizophr Bull 2021;47:277-83.
92. Zwicker A, MacKenzie LE, Drobinin V et al. Neurodevelopmental and genetic determinants of exposure to adversity among youth at risk for mental illness. J Child Psychol Psychiatry 2020;61:536-44.
93. Socrates A, Maxwell J, Glanville KP et al. Investigating the effects of genetic risk of schizophrenia on behavioural traits. NPJ Schizophr 2021;7:2.
94. Schiele MA, Gottschalk MG, Domschke K. The applied implications of epigenetics in anxiety, affective and stress-related disorders – a review and synthesis on psychosocial stress, psychotherapy and prevention. Clin Psychol Rev 2020;77:101830.
95. Beards S, Gayer-Anderson C, Borges S et al. Life events and psychosis: a review and meta-analysis. Schizophr Bull 2013;39:740-7.
96. Wu S, Wu F, Ding Y et al. Advanced parental age and autism risk in children: a systematic review and meta-analysis. Acta Psychiatr Scand 2017;135:29-41.
97. van Os J, Reininghaus U. Psychosis as a transdiagnostic and extended phenotype in the general population. World Psychiatry 2016;15:118-24.
98. Karcher NR, Barch DM, Avenevoli S et al. Assessment of the Prodromal Questionnaire-Brief Child Version for measurement of self-reported psychoticlike experiences in childhood. JAMA Psychiatry 2018;75:853-61.
99. Sullivan SA, Kounali D, Cannon M et al. A population-based cohort study examining the incidence and impact of psychotic experiences from childhood to adulthood, and prediction of psychotic disorder. Am J Psychiatry 2020;177:308-17.
100. Fusar-Poli P, Raballo A, Parnas J. What is an attenuated psychotic symptom? On the importance of the context. Schizophr Bull 2017;43:687-92.
101. Schultze-Lutter F, Michel C, Ruhrmann S et al. Prevalence and clinical significance of DSM-5-attenuated psychosis syndrome in adolescents and young adults in the general population: the Bern Epidemiological At-Risk (BEAR) study. Schizophr Bull 2014;40:1499-508.
102. Fusar-Poli P, Salazar de Pablo G, Correll C et al. Prevention of psychosis: advances in detection, prognosis and intervention. JAMA Psychiatry 2020;77:755-65.
103. Parnas J, Henriksen MG. Epistemological error and the illusion of phenomenological continuity. World Psychiatry 2016;15:126-7.
104. Varese F, Smeets F, Drukker M et al. Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective-and cross-sectional cohort studies. Schizophr Bull 2012;38:661-71.
105. International Alliance of Mental Health Research Funders. Driving the adoption of shared measures. https://www.iamhrf.org/projects.
106. Firth J, Wootton RE, Carvalho AF. Toward preventive psychiatry: the role of advanced epidemiological methods. Am J Psychiatry 2020;177:888-90.
107. Salazar de Pablo G, De Micheli A, Nieman DH et al. Universal and selective interventions to promote good mental health in young people: systematic review and meta-analysis. Eur Neuropsychopharmacol 2020;41:28-39.
108. Fusar-Poli P, Salazar de Pablo G, De Micheli A et al. What is good mental health? A scoping review. Eur Neuropsychopharmacol 2020;31:33-46.